Pharmacyclics LLC
Clinical trials sponsored by Pharmacyclics LLC, explained in plain language.
A biopharmaceutical company known for the cancer drug Imbruvica, owned by AbbVie.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Two-Drug combo aims to push CLL into deep remission
Disease control CompletedResearchers are testing whether combining ibrutinib and venetoclax can help people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The trial assigns participants to either a fixed course of the two drugs or a course guided by a sensitive test…
Phase 2 • Sponsor: Pharmacyclics LLC. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New combo shows promise in slowing follicular lymphoma progression
Disease control CompletedThis study tested whether adding the drug ibrutinib to standard rituximab therapy helps people with untreated follicular lymphoma live longer without their cancer getting worse. About 445 patients aged 60 or older (or 60-69 with other health issues) took part. The main goal was t…
Phase 3 • Sponsor: Pharmacyclics LLC. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Could a cancer drug ease a devastating transplant complication in kids?
Disease control CompletedThis study tested the drug ibrutinib in 59 children with chronic graft-versus-host disease (cGVHD), a serious condition that can occur after a stem cell transplant. The goal was to find the best dose and see if it is safe. Participants had moderate or severe cGVHD that did not im…
Phase 1/2 • Sponsor: Pharmacyclics LLC. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC